Zamiri Parisa 4
4 · CalciMedica, Inc. · Filed Mar 27, 2023
Insider Transaction Report
Form 4
Zamiri Parisa
Chief Medical Officer
Transactions
- Disposition to Issuer
Common Stock
2023-03-23+42,771→ 46,883 total - Disposition to Issuer
Restricted Stock Unit
2023-03-23−42,771→ 0 total→ Common Stock (42,771 underlying) - Tax Payment
Common Stock
2023-03-23$5.50/sh−17,901$98,456→ 28,982 total
Footnotes (2)
- [F1]Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the "Merger Agreement"), by and among CalciMedica, Inc. ("Private CalciMedica"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer ("Merger Sub"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the "Merger"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Parisa Zamiri's options and restricted stock units ("RSUs") were fully accelerated and the RSUs were settled on March 23, 2023.
- [F2]Includes 8,618 restricted stock units converted to common stock that were previously reported on March 3, 2023 that settled on March 23, 2023.